Multiple low dose therapy as an effective strategy to treat EGFR inhibitor-resistant NSCLC tumours

Journal: Nature Communications

Published: 2020-06-22

DOI: 10.1038/s41467-020-16952-9

Affiliations: 11

Authors: 18

Go to article
Institutions Share
Division of Molecular Carcinogenesis, NKI, Netherlands 0.19
Oncode Institute, Netherlands 0.19
Program Against Cancer Therapeutic Resistance (ProCure), IDIBELL, Spain 0.17
Division of Molecular Oncology and Immunology, NKI, Netherlands 0.17
Division of Experimental Animal Pathology, NKI, Netherlands 0.06
Vall d'Hebron Institute of Oncology (VHIO), HUVH ICS, Spain 0.06
Autonomous University of Barcelona (UAB), Spain 0.06
Division of Pharmacology, NKI, Netherlands 0.06
Instituto Gonçalo Moniz (IGM), FIOCRUZ, Brazil 0.03
XenOPAT SL, Spain 0.03
Faculty of Science, VU Amsterdam, Netherlands 0.02

Return

Except where otherwise noted © 2021 Springer Nature Limited. All Rights Reserved.
partner of AGORA, HINARI, OARE, INASP, ORCID, CrossRef and COUNTER